Compare CWT & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWT | XENE |
|---|---|---|
| Founded | 1926 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | N/A | 2014 |
| Metric | CWT | XENE |
|---|---|---|
| Price | $44.60 | $42.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $54.50 | $53.55 |
| AVG Volume (30 Days) | 369.2K | ★ 795.7K |
| Earning Date | 10-30-2025 | 11-03-2025 |
| Dividend Yield | ★ 2.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.29 | N/A |
| Revenue | ★ $1,002,357,000.00 | $7,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.38 | N/A |
| P/E Ratio | $19.53 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $41.64 | $26.74 |
| 52 Week High | $51.63 | $45.01 |
| Indicator | CWT | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 58.12 |
| Support Level | $43.94 | $39.09 |
| Resistance Level | $46.32 | $45.01 |
| Average True Range (ATR) | 0.92 | 1.42 |
| MACD | -0.01 | 0.33 |
| Stochastic Oscillator | 28.91 | 64.82 |
California Water Service Group is a U.S. water and utilities holding company based in California. The company engages in the production, treatment, storage, distribution, and sale of water for various uses. The firm operates through its subsidiaries, which can be divided between regulated and unregulated businesses. The regulated public utilities subsidiaries operate in California, New Mexico, Washington, and Hawaii. The unregulated subsidiaries provide water utility services to private companies and municipalities. The company derives the majority of its revenue from its operations in California and, overall, from residential customers.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.